CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. (CTMX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ctmx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CytomX Therapeutics, Inc. (CTMX) measures how much investors pay for each dollar of the company's trailing earnings. CTMX's current PE ratio of N/A is calculated by dividing its stock price of $2.94 by its TTM earnings per share of -$0.33.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2013 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CytomX Therapeutics, Inc.You CTMX | $474M | N/A | — | -$0.33 |
 Astria Therapeutics, Inc. ATXS | $718M | N/A | — | -$1.68 |
 ArriVent BioPharma, Inc. Common Stock AVBP | $1.4B | N/A | — | -$4.32 |
 Anavex Life Sciences Corp. AVXL | $238M | N/A | — | -$0.54 |
 Ginkgo Bioworks Holdings, Inc. DNA | $531M | N/A | — | -$5.64 |
 Erasca, Inc. ERAS | $3.9B | N/A | — | -$0.44 |
 Iovance Biotherapeutics, Inc. IOVA | $1.5B | N/A | — | -$1.09 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.13 | — | |
2024-12-31 FY2024 | 2.73x | $0.38 | — | |
2023-12-31 FY2023 | — | $-0.01 | — | |
2022-12-31 FY2022 | — | $-1.51 | — | |
2021-12-31 FY2021 | — | $-1.81 | — | |
2020-12-31 FY2020 | — | $-1.40 | — | |
2019-12-31 FY2019 | — | $-2.26 | — | |
2018-12-31 FY2018 | — | $-2.03 | — | |
2017-12-31 FY2017 | — | $-1.16 | — | |
2016-12-31 FY2016 | — | $-1.63 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CytomX Therapeutics, Inc. (CTMX) measures how much investors pay for each dollar of the company's trailing earnings. CTMX's current PE ratio of N/A is calculated by dividing its stock price of $2.94 by its TTM earnings per share of -$0.33.
Frequently asked questions
CTMX pe ratio · 6 questionsCTMX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.94 and TTM EPS of -$0.33. Data sourced from Financial Modeling Prep via CTMX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CytomX Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08